FORTREA HOLDINGS INC

Fortrea’s new partnership with Omico accelerates biomarker‑driven cancer trials, combining patient‑matching, genomic profiling, and global clinical expertise.

Fortrea (FTRE) sees a 0.31% dip but holds strong above its 200‑day SMA, underlining solid momentum in clinical‑trial and patient‑access services.